Format

Send to

Choose Destination
Neurology. 2012 May 29;78(22):1743-53. doi: 10.1212/WNL.0b013e318258300d. Epub 2012 Apr 25.

IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment.

Author information

1
Department of Neurology, Charité University Medicine Berlin, Berlin. harald.pruess@charite.de

Abstract

OBJECTIVE:

To report that antibodies to synaptic proteins may occur in association with slow, progressive cognitive decline.

METHODS:

A total of 24 patients with progressive cognitive dysfunction of unclear etiology were examined for onconeuronal and synaptic receptor antibodies. The effect of serum was examined in cultures of dissociated mouse hippocampal neurons.

RESULTS:

Seven patients had immunoglobulin A (IgA), but no immunoglobulin G (IgG), antibodies against NMDA receptor (NMDAR). Anti-NMDAR IgA positive patients' serum, but not serum from control individuals, caused dramatic decrease of the levels of NMDAR and other synaptic proteins in neurons, along with prominent changes in NMDAR-mediated currents. These effects correlated with the titer of IgA NMDAR antibodies and were reversed after removing patients' serum from the culture media. When available, comprehensive clinical assessment and brain metabolic imaging showed neurologic improvement after immunotherapy.

CONCLUSIONS:

A subset of patients with slowly progressive cognitive impairment has an underlying synaptic autoimmunity that decreases the density of NMDAR and other synaptic proteins, and alters synaptic currents. This autoimmunity can be demonstrated examining patients' serum and CSF for NMDAR IgA antibodies, identifying possible candidates for immunotherapy.

PMID:
22539565
PMCID:
PMC3359581
DOI:
10.1212/WNL.0b013e318258300d
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center